Interval cancers using a quantitative faecal immunochemical test (FIT) for haemoglobin when colonoscopy capacity is limited

Journal of Medical Screening

Volumn 23, Issue 3, 2016, Pages 130-134

  Digby, Jayne ^a   Fraser, Callum G ^a   Carey, Francis A ^a   Lang, Jaroslaw ^b   Stanners, Greig ^b   Steele, Robert J C ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b INFORMATION SERVICES DIVISION   (United Kingdom)

Author keywords

Colorectal cancer; Faecal haemoglobin; Faecal immunochemical test; Faecal occult blood test; Interval cancers

Indexed keywords

GUAIAC;

AGED; CHEMISTRY; COLONOSCOPY; COLORECTAL TUMOR; EARLY CANCER DIAGNOSIS; FECES; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MASS SCREENING; MIDDLE AGED; OCCULT BLOOD; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PROCEDURES; SCOTLAND; UTILIZATION;

AGED; COLONOSCOPY; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; FECES; FEMALE; GUAIAC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MASS SCREENING; MIDDLE AGED; OCCULT BLOOD; OUTCOME ASSESSMENT (HEALTH CARE); PREDICTIVE VALUE OF TESTS; SCOTLAND;

EID: 84986582612     PISSN: 09691413     EISSN: 14755793     Source Type: Journal    
DOI: 10.1177/0969141315609634     Document Type: Article

References (26)

1. Sanduleanu S, le Clercq CM, Dekker E, et al. On behalf of the Expert Working Group on ‘Right-sided lesions and interval cancers’, Colorectal Cancer Screening Committee, World Endoscopy Organization. Definition and taxonomy of interval colorectal cancers: A proposal for standardising nomenclature. Gut 2014; 64: 1257–1267.
2. Towler B, Irwig L, Glasziou P, et al. A systematic review of the effects of screening for colorectal cancer using the faecal occult blood test, Hemoccult. Br Med J 1998; 317: 559–565.
3. Hardcastle JD, Chamberlain JO, Robinson MHE, et al. Randomised controlled trial of faecaloccultblood screening for colorectal cancer. Lancet 1996; 348: 1472–1477.
4. Kronborg O, Fenger C, Olsen J, et al. Randomised study of screening for colorectal cancer with faecaloccultblood test. Lancet 1996; 348: 1467–1471.
5. Faivre J, Arveux P, Milan C, et al. Participation in mass screening for colorectal cancer: results of screening and rescreening from the Burgundy study. Eur J Cancer Prev 1991; 1: 49–55.
6. Jensen BM, Kronborg O, Fenger C. Interval cancers in screening with fecal occult blood test for colorectal cancer. Scand J Gastroenterol 1992; 27: 779–782.
7. Steele RJ, McClements P, Watling C, et al. Interval cancers in a FOBT-based colorectal cancer population screening programme: implications for stage, gender and tumour site. Gut 2012; 61: 576–581.
8. Tazi MA, Faivre J, Lejeune C, et al. Interval cancers in a community-based programme of colorectal cancer screening with faecal occult blood test. Eur J Cancer Prev 1999; 8: 13–15.
9. Gill MD, Bramble MG, Rees CJ, et al. Comparison of screen-detected and interval colorectal cancers in the Bowel Cancer Screening Programme. Br J Cancer 2012; 107: 417–421.
10. Brenner H, Chang-Claude J, Seiler CM, et al. Interval cancers after negative colonoscopy: population-based case-control study. Gut 2012; 61: 15768–15762.
11. Cooper GS, Xu F, Barnholtz Sloan JS, et al. Prevalence and predictors of interval colorectal cancers in Medicare beneficiaries. Cancer 2012; 118: 3044–3052.
12. Singh H, Turner D, Xue L, et al. Risk of developing colorectal cancer following a negative colonoscopy examination: Evidence for a 10-year interval between colonoscopies. JAMA 2006; 295: 2366–2373.
13. Singh H, Nugent Z, Demers AA, et al. Rate and predictors of early/missed colorectal cancers after colonoscopy in Manitoba: A population-based study. Am J Gastroenterol 2010; 105: 2588–2596.
14. Farrar WD, Sawhney MS, Nelson DB, et al. Colorectal cancers found after a complete colonoscopy. Clin Gastroenterol Hepatol 2006; 4: 1259–1264.
15. Hosokawa O, Shirasaki S, Kaizaki Y, et al. Invasive colorectal cancer detected up to 3 years after a colonoscopy negative for cancer. Endoscopy 2003; 35: 506–510.
16. Launoy G, Smith TC, Duffy SW, et al. Colorectal cancer mass-screening: Estimation of faecal occult blood test sensitivity, taking into account cancer mean sojourn time. Int J Cancer 1997; 73: 220–224.
17. Allison JE, Fraser CG, Halloran SP, et al. Population screening for colorectal cancer means getting FIT: The past, present, and future of colorectal cancer screening using the fecal immunochemical test for hemoglobin (FIT). Gut Liver 2014; 8: 117–130.
18. Rabeneck L, Rumble RB, Thompson F, et al. Fecal immunochemical tests compared with guaiac fecal occult blood tests for population-based colorectal cancer screening. Can J Gastroenterol 2012; 26: 131–147.
19. Steele RJC, McDonald PJ, Digby J, et al. Clinical outcomes using a faecal immunochemical test for haemoglobin as a first-line test in a national programme constrained by colonoscopy capacity. United European Gastroenterology J 2013; 1: 198–205.
20. Fraser CG, Digby J, McDonald PJ, et al. Experience with a two-tier reflex gFOBT/FIT strategy in a national bowel screening programme. J Med Screen 2012; 19: 8–13.
21. The Information Services Division. The Scottish Index of Multiple Deprivation (SIMD). Available from: http://www.isdscotland.org/Products-and-Services/GPD-Support/Deprivation/SIMD/ (accessed 16 March 2015).
22. Young GP, Symonds EL, Allison JE, et al. Advances in fecal occult blood tests: The FIT revolution. Dig Dis Sci 2015; 60: 609–622.
23. Fraser CG, Rubeca T, Rapi S, et al. Faecal haemoglobin concentrations vary with sex and age, but data are not transferable across geography for colorectal cancer screening. Clin Chem Lab Med 2014; 52: 1211–1216.
24. Zorzi M, Fedato C, Grazzini G, et al. High sensitivity of five colorectal screening programmes with faecal immunochemical test in the Veneto Region, Italy. Gut 2011; 60: 944–949.
25. McDonald PJ, Strachan JA, Digby J, et al. Faecal haemoglobin concentrations by gender and age: implications for population-based screening for colorectal cancer. Clin Chem Lab Med 2011; 50: 9354–9350.
26. Auge JM, Pellise M, Escudero JM, et al. Risk stratification for advanced colorectal neoplasia according to fecal hemoglobin concentration in a colorectal cancer screening program. Gastroenterol 2014; 147: 628–636.